SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:prod.swepub.kib.ki.se:137291598"
 

Search: id:"swepub:oai:prod.swepub.kib.ki.se:137291598" > Inhibition of C1-Te...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Inhibition of C1-Ten PTPase activity reduces insulin resistance through IRS-1 and AMPK pathways

Jeong, H (author)
Koh, A (author)
Lee, J (author)
show more...
Park, D (author)
Lee, JO (author)
Lee, MN (author)
Jo, KJ (author)
Tran, HNK (author)
Kim, E (author)
Min, BS (author)
Kim, HS (author)
Berggren, PO (author)
Karolinska Institutet
Ryu, SH (author)
show less...
 (creator_code:org_t)
2017-12-19
2017
English.
In: Scientific reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 7:1, s. 17777-
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Insulin resistance causes type 2 diabetes; therefore, increasing insulin sensitivity is a therapeutic approach against type 2 diabetes. Activating AMP-activated protein kinase (AMPK) is an effective approach for treating diabetes, and reduced insulin receptor substrate-1 (IRS-1) protein levels have been suggested as a molecular mechanism causing insulin resistance. Thus, dual targeting of AMPK and IRS-1 might provide an ideal way to treat diabetes. We found that 15,16-dihydrotanshinone I (DHTS), as a C1-Ten protein tyrosine phosphatase inhibitor, increased IRS-1 stability, improved glucose tolerance and reduced muscle atrophy. Identification of DHTS as a C1-Ten inhibitor revealed a new function of C1-Ten in AMPK inhibition, possibly through regulation of IRS-1. These findings suggest that C1-Ten inhibition by DHTS could provide a novel therapeutic strategy for insulin resistance-associated metabolic syndrome through dual targeting of IRS-1 and AMPK.

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view